Skip to main content

Table 1 Summary of clinical parameters and analysis of HIV before after H1N1 vaccination

From: H1N1 influenza vaccination in HIV-infected women on effective antiretroviral treatment did not induce measurable antigen-driven proliferation of the HIV-1 proviral reservoir

Subject ID

Time-point

Pandemic H1N1 HAI Titer

Seasonal H1N1 HAI Titer

CD4+ (cells/mm3)

Days on ART

Copies HIV DNA/million PBMC

Plasma RNA (copies/mL)

# HIV DNA Seq.

Divergence median (95% CI)

Diversity median (95% CI)

# Mono-typic sequences

% Mono-typic

1

Entry

5

5

140

125

358

112

20

.080 (.047 to 113)

.052 (.007 to .097)

2

10

Week 3

20

5

–

206

38.4

36

.08 (.060 to .100)

.056 (.019 to .093)

10

28

2

Entry

10

10

337

77

22

ND

18

.023 (.020 to .027)

.032 (.019 to .045)

3

17

Week 3

20

10

–

17

ND

23

.017 (.014 to .023)

.026 (.014 to .038)

7

30

3

Entry

10

10

475

386 a

398

NA

21

.029 (.018 to .040)

.029 (.012 to .046)

2

10

Week 3

10

5

–

614

NA

19

.029 (.010 to .048)

.034 (.012 to .056)

4

21

4

Entry

5

10

623

882 a

123

NA

21

.019 (.009 to .029)

.020 (−.001 to .041)

10

48

Week 3

80

10

–

157

NA

20

.020 (.009 to .031)

.019 (.006 to .032)

6

30

5

Entry

5

40

1383

57

3

NA

22

.024 (.022 to .026)

.019 (.009 to .029)

10

45

Week 3

160

20

–

10

NA

20

.024 (.017 to .031)

.019 (.010 to .028)

8

40

6

Entry

40

40

400

302 a

24

<8

28

.017 (.006 to .028)

.017 ( to .003.037)

7

25

Week 3

320

40

–

6

ND

24

.017 (.007 to .027)

.02 (.003 to .037)

8

33

7

Entry

80

40

608

2494 a

70

ND

19

.016 (.010 to .022)

.015 (.004 to .026)

7

37

Week 3

160

40

–

3

ND

20

.016 (.013 to .019)

.015 (.007 to .023)

6

30

8

Entry

20

20

381

106

52

11.4

24

.054 (.023 to .085)

.037 (.004 to .070)

8

33

Week 3

160

20

–

57

<8

23

.052 (.034 to .070)

.042 (.010 to .074)

6

26

9

Entry

20

40

501

56

122

ND

21

.045 (.013 to .077)

.045 (.020 to .070)

8

40

Week 3

160

20

–

186

ND

20

.049 (.027 to .071)

.043 (.019 to .067)

8

40

10

Entry

80

20

712

85

153

NA

20

.050 (.016 to .084)

.059 (.022 to .096)

5

25

Week 3

1280

20

–

26

NA

24

.052 (.018 to .086)

.064 (.027 to .101)

4

17

  1. Participants indicated in italic (Group 2, Participants 8, 9, and 10) were hypothesized but not observed to demonstrate H1N1-antigen stimulated proliferation of HIV-1-infected CD4+ cells, whereas participants underlined (Group 1, Participants 1–7) were not expected to demonstrate H1N1-antigen stimulated proliferation of HIV-1-infected CD4+ cells
  2. ND not detected, NA adequate sample not available
  3. aIndicate participants that initiated ART prior to the 2009 H1N1 pandemic
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us